Asieris raises series B round

Asieris Pharmaceuticals Co. Ltd. (Taizhou, China) said on Dec. 27, 2017, that it raised RMB110-RMB120 million ($16.8-$18.3 million) in a series B round led by Lapam Capital. Fellow new investors Kaitai Capital and Zhongguancun Qihang Industry Fund also participated, as did existing investor Phoenix Fund. The company expects a final figure in January. Asieris said the over-booked round should fund operations for about 18 months.

This year, Asieris plans to begin a U.S. Phase II trial of lead candidate APL-1202 to treat non-muscle invasive bladder cancer (NMIBC). Data from an ongoing Chinese Phase III trial to treat relapsed NMIBC are expected by year end...